clinical trial · NCT04918186
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Canadian Cancer Trials Group·phase2·recruiting·n = 60
Ovarian CancerDurvalumabBA3011BA3021ENB003Toripalimab
brief summary
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
started
May 3, 2022
primary completion
Jun 30, 2026
completion
Dec 31, 2026
last updated
May 12, 2026
detailed description
This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.
official title
An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol